Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Braz. j. med. biol. res ; 53(6): e8885, 2020. tab, graf
Article in English | ColecionaSUS, LILACS, ColecionaSUS | ID: biblio-1132519

ABSTRACT

In this study, we aimed to analyze the anti-cancer effects of β-elemene combined with paclitaxel for ovarian cancer. RT-qPCR, MTT assay, western blot, flow cytometry, and immunohistochemistry were used to analyze in vitro and in vivo anti-cancer effects of combined treatment of β-elemene and paclitaxel. The in vitro results showed that β-elemene+paclitaxel treatment markedly inhibited ovarian cancer cell growth, migration, and invasion compared to either paclitaxel or β-elemene treatment alone. Results demonstrated that β-elemene+paclitaxel induced apoptosis of SKOV3 cells, down-regulated anti-apoptotic Bcl-2 and Bcl-xl gene expression and up-regulated pro-apoptotic P53 and Apaf1 gene expression in SKOV3 cells. Administration of β-elemene+paclitaxel arrested SKOV3 cell cycle at S phase and down-regulated CDK1, cyclin-B1, and P27 gene expression and apoptotic-related resistant gene expression of MDR1, LRP, and TS in SKOV3 cells. In vivo experiments showed that treatment with β-elemene+paclitaxel significantly inhibited ovarian tumor growth and prolonged the overall survival of SKOV3-bearing mice. In addition, the treatment inhibited phosphorylated STAT3 and NF-κB expression in vitro and in vivo. Furthermore, it inhibited migration and invasion through down-regulation of the STAT-NF-κB signaling pathway in SKOV3 cells. In conclusion, the data suggested that β-elemene+paclitaxel can inhibit ovarian cancer growth via down-regulation of the STAT3-NF-κB signaling pathway, which may be a potential therapeutic strategy for ovarian cancer therapy.


Subject(s)
Animals , Male , Female , Rabbits , Ovarian Neoplasms/drug therapy , Sesquiterpenes/administration & dosage , Cell Movement/drug effects , NF-kappa B/adverse effects , Paclitaxel/administration & dosage , Apoptosis/drug effects , Cell Proliferation/drug effects , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/pathology , Immunohistochemistry , Transfection , Signal Transduction , Blotting, Western , NF-kappa B/metabolism , Cell Line, Tumor , Real-Time Polymerase Chain Reaction , Mice, Inbred BALB C
2.
Arch. endocrinol. metab. (Online) ; 62(2): 212-220, Mar.-Apr. 2018. tab, graf
Article in English | LILACS | ID: biblio-887651

ABSTRACT

ABSTRACT Objective To observe the effect of short-term insulin intensive treatment on the monocyte chemoattractant protein-1 (MCP-1) as well as on the nuclear factor-kappa B (NF-κB) expression of peripheral blood monocyte. This is also in addition to observing the serum MCP-1 level in newlydiagnosed type 2 diabetic patients and probing its anti-inflammation effects. Subjects and methods Twenty newly-diagnosed type 2 diabetic patients were treated with an insulin intensive treatment for 2 weeks. MCP-1 and NF-κB expression on the monocyte surface were measured with flow cytometry, the serum MCP-1 level was measured by enzyme linked immunosorbent assay (ELISA) during pretreatment and post-treatment. Results After 2 weeks of the treatment, MCP-1 and NF-κB protein expression of peripheral blood monocyte and serum MCP-1 levels decreased significantly compared with those of pre-treatment, which were (0.50 ± 0.18)% vs (0.89 ± 0.26)% (12.22 ± 2.80)% vs (15.53 ± 2.49)% and (44.53 ± 3.97) pg/mL vs (49.53 ± 3.47) pg/mL, respectively (P < 0.01). The MCP-1 expression on monocyte surface had a significant positive relationship with serum MCP-1 levels (r = 0.47, P < 0.01). Conclusions Short-term insulin intensive therapy plays a role in alleviating the increased inflammation reaction in type 2 diabetics.


Subject(s)
Humans , Male , Female , Middle Aged , Monocytes/chemistry , NF-kappa B/adverse effects , Chemokine CCL2/drug effects , Diabetes Mellitus, Type 2/drug therapy , Inflammation/prevention & control , Insulin/administration & dosage , Enzyme-Linked Immunosorbent Assay , Case-Control Studies , NF-kappa B/blood , Chemokine CCL2/blood , Diabetes Mellitus, Type 2/blood , Flow Cytometry
3.
Braz. j. med. biol. res ; 51(11): e7338, 2018. tab, graf
Article in English | LILACS | ID: biblio-951725

ABSTRACT

Hypertensive renal damage generally occurs during the middle and late stages of hypertension, which is typically characterized by proteinuria and renal inflammation. Captopril, an angiotensin-converting enzyme (ACE) inhibitor, has been widely used for therapy of arterial hypertension and cardiovascular diseases. However, the protective effects of captopril on hypertension-induced organ damage remain elusive. The present study was designed to explore the renoprotective action of captopril in spontaneously hypertensive rats (SHR). The 6-week-old male SHR and age-matched Wistar-Kyoto rats were randomized into long-term captopril-treated (34 mg/kg) and vehicle-treated groups. The results showed that in SHR there was obvious renal injury characterized by the increased levels of urine albumin, total protein, serum creatinine, blood urea nitrogen, renal inflammation manifested by the increased mRNA and protein expression of inflammatory factors including tumor necrosis factor-α, interleukin (IL)-1β, IL-6, and inducible nitric oxide synthase, and enhanced nuclear factor-κB (NF-κB) activation. Captopril treatment could lower blood pressure, improve renal injury, and suppress renal inflammation and NF-κB activation in SHR rats. In conclusion, captopril ameliorates renal injury and inflammation in SHR possibly via inactivation of NF-κB signaling.


Subject(s)
Animals , Male , Rats , Proteinuria/prevention & control , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Captopril/therapeutic use , NF-kappa B/adverse effects , Hypertension/drug therapy , Nephritis/prevention & control , Antihypertensive Agents/therapeutic use , Proteinuria/etiology , Rats, Inbred SHR , Rats, Inbred WKY , Signal Transduction , Hypertension/complications , Nephritis/etiology
4.
LMJ-Lebanese Medical Journal. 2006; 54 (4): 196-199
in English | IMEMR | ID: emr-78908

ABSTRACT

Transitional cell carcinoma [TCC] of the bladder remains a significant health problem worldwide. The molecular mechanisms of tumor development and progression are complicated but likely involve the interaction of tumor suppressor genes, oncogenes, cell cycle regulatory proteins and other factors. Hence, this study attempts to explore the role of nuclear factor-kB [NF-KB] in the TCC of the bladder in correlation with different clinicopathological criteria which are tumor grade, muscle invasion by the tumor, schistosomiasis and presentation whether primary or recurrent tumor. Twenty patients with TCC of the bladder were included in the study from June 2003 to June 2004, and were diagnosed by histopathology. The expressions of the transcription factor NF-kB were studied by in situ hybridization technique [ISH]. The results showed that there was a significant correlation [p<0.05] with muscle invasion and schistosomiasis but not with other criteria. The current study showed the possible role of the transcription factor [NF-kB] in TCC of the bladder


Subject(s)
Humans , Male , Female , Carcinoma, Transitional Cell/etiology , NF-kappa B/adverse effects , In Situ Hybridization , Schistosomiasis
SELECTION OF CITATIONS
SEARCH DETAIL